{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:57:20Z","timestamp":1781236640922,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M713859"],"award-info":[{"award-number":["2022M713859"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","award":["2005L03565"],"award-info":[{"award-number":["2005L03565"]}],"id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","award":["2006L00603"],"award-info":[{"award-number":["2006L00603"]}],"id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012397","name":"Army Medical University","doi-asserted-by":"publisher","award":["2007L03927"],"award-info":[{"award-number":["2007L03927"]}],"id":[{"id":"10.13039\/501100012397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jgar.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,21]],"date-time":"2023-03-21T08:59:50Z","timestamp":1679389190000},"page":"120-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Pharmacokinetic\/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation"],"prefix":"10.1016","volume":"33","author":[{"given":"Pan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglan","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0121-0769","authenticated-orcid":false,"given":"Yongchuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2023.03.002_bib0001","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMp078193","article-title":"The ongoing regulation of generic drugs","volume":"357","author":"Frank","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10156-012-0437-0","article-title":"Generic antibiotics in Japan","volume":"18","author":"Fujimura","year":"2012","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2125.2010.03718.x","article-title":"Generic and therapeutic substitutions in the UK: are they a good thing?","volume":"70","author":"Duerden","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/cid\/cit769","article-title":"Efficacy and quality of antibacterial generic products approved for human use: a systematic review","volume":"58","author":"Tattevin","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3349\/ymj.2020.61.4.301","article-title":"Comparison of in vivo pharmacokinetics and pharmacodynamics of vancomycin products available in Korea","volume":"61","author":"Kim","year":"2020","journal-title":"Yonsei medical journal"},{"key":"10.1016\/j.jgar.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3389\/fphar.2019.00881","article-title":"Meor Mohd Affandi MMR, et\u00a0al. Levofloxacin: insights into antibiotic resistance and product quality","volume":"10","author":"Izadi","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/AAC.00350-13","article-title":"Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: the case of meropenem","volume":"58","author":"Agudelo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1023\/A:1011907920641","article-title":"Modeling of pharmacokinetic\/pharmacodynamic (PK\/PD) relationships: concepts and perspectives","volume":"16","author":"Derendorf","year":"1999","journal-title":"Pharmaceutical research"},{"key":"10.1016\/j.jgar.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jiac.2015.02.001","article-title":"Applications of the pharmacokinetic\/pharmacodynamic (PK\/PD) analysis of antimicrobial agents","volume":"21","author":"As\u00edn-Prieto","year":"2015","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1128\/AAC.00182-11","article-title":"Pharmacokinetic\/pharmacodynamic (PK\/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization","volume":"55","author":"Nielsen","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0011","article-title":"Competence mining of vancomycin (VAN) in the management of infections due to bacterial strains with high VAN minimum inhibitory concentrations (MICs): a novel dosing strategy based on pharmacokinetic\/pharmacodynamic modeling","volume":"12","author":"Song","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/jac\/dki079","article-title":"Standardization of pharmacokinetic\/pharmacodynamic (PK\/PD) terminology for anti-infective drugs: an update","volume":"55","author":"Mouton","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1128\/AAC.43.7.1756","article-title":"Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus","volume":"43","author":"Dong","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41429-017-0024-9","article-title":"In vitro activity of minocycline combined with aminoglycosides against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae","volume":"71","author":"Wentao","year":"2018","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2023.03.002_bib0017","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/fmb-2016-0140","article-title":"Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic\/pharmacodynamic analysis","volume":"12","author":"Yang","year":"2017","journal-title":"Future microbiology"},{"key":"10.1016\/j.jgar.2023.03.002_bib0018","unstructured":"CERTARA. Phoenix Assistance Library, WNL Classic Models, https:\/\/onlinehelp.certara.com\/phoenix\/8.2\/topics\/pkmodels.htm; 2019 [accessed 2022.08.18]."},{"key":"10.1016\/j.jgar.2023.03.002_bib0019","doi-asserted-by":"crossref","first-page":"11339","DOI":"10.1038\/s41598-021-90709-2","article-title":"Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy","volume":"11","author":"Fedrigo","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2023.03.002_bib0020","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1592\/phco.20.5.417.35062","article-title":"Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters","volume":"20","author":"Pickerill","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jgar.2023.03.002_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/jop.2011.0072","article-title":"Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones","volume":"28","author":"Segreti","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jgar.2023.03.002_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0924-8579(02)00028-6","article-title":"Breakpoints: current practice and future perspectives","volume":"19","author":"Mouton","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2023.03.002_bib0023","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s10156-009-0714-8","article-title":"Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China","volume":"15","author":"Zhang","year":"2009","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0024","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1093\/jac\/dkl135","article-title":"Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration","volume":"57","author":"Olofsson","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrmicro3270","article-title":"Microbiological effects of sublethal levels of antibiotics","volume":"12","author":"Andersson","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11095-007-9511-1","article-title":"Pharmaceutical quality by design: product and process development, understanding, and control","volume":"25","author":"Yu","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.jgar.2023.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/rcm.7675","article-title":"Non-target impurity profiling of marketplace Cetirizine using high-resolution mass spectrometry and multivariate data analysis","volume":"30","author":"Zhou","year":"2016","journal-title":"Rapid Commun Mass Spectrom"},{"key":"10.1016\/j.jgar.2023.03.002_bib0028","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jps.24299","article-title":"Excipient variability and its impact on dosage form functionality","volume":"104","author":"Dave","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.jgar.2023.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/S0149-2918(03)80157-1","article-title":"The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs","volume":"25","author":"Borgheini","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.jgar.2023.03.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195258","article-title":"Invasive infection caused by Klebsiella pneumoniae is a disease affecting patients with high comorbidity and associated with high long-term mortality","volume":"13","author":"Vading","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2023.03.002_bib0031","doi-asserted-by":"crossref","first-page":"f3140","DOI":"10.1136\/bmj.f3140","article-title":"Diagnosis and management of recurrent urinary tract infections in non-pregnant women","volume":"346","author":"Gupta","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.jgar.2023.03.002_bib0032","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jmii.2011.12.019","article-title":"Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli","volume":"49","author":"Wu","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2023.03.002_bib0033","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12889-019-6804-3","article-title":"Fluoroquinolone consumption and Escherichia coli resistance in Japan: an ecological study","volume":"19","author":"Terahara","year":"2019","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jgar.2023.03.002_bib0034","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/jac\/dkg269","article-title":"The mutant selection window and antimicrobial resistance","volume":"52","author":"Drlica","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0035","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3389\/fmicb.2019.01638","article-title":"Amoxicillin administration regimen and resistance mechanisms of Staphylococcus aureus established in tissue cage infection model","volume":"10","author":"Yao","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0036","article-title":"Oridonin: a review of its pharmacology, pharmacokinetics antd oxicity","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0037","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1128\/AAC.01044-09","article-title":"Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator","volume":"54","author":"Vesga","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0038","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coph.2017.09.009","article-title":"Use of Monte Carlo simulation and considerations for PK-PD targets to support antibacterial dose selection","volume":"36","author":"Trang","year":"2017","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jgar.2023.03.002_bib0039","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s10096-021-04252-z","article-title":"Semi-mechanistic PK\/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii","volume":"40","author":"Mohd Sazlly Lim","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2023.03.002_bib0040","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/jac\/dkac031","article-title":"Oral levofloxacin: population pharmacokinetics model and pharmacodynamics study in bone and joint infections","volume":"77","author":"Canou\u00ef","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2023.03.002_bib0041","first-page":"886","article-title":"Population pharmacokinetics and pharmacodynamics modeling of oral levofloxacin","volume":"99","author":"Jaruratanasirikul","year":"2018","journal-title":"J Med Assoc Thai"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716523000474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:59:25Z","timestamp":1761991165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716523000474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"alternative-id":["S2213716523000474"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2023.03.002","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic comparison between generic and brand-name levofloxacin based on Monte Carlo simulation","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}